Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Muscle Targeted AOC is an investigational antibody-oligonucleotide conjugate (AOC) being developed by Aera Therapeutics. The program is designed to deliver oligonucleotide therapeutics selectively to muscle tissue, aiming to treat diseases affecting the muscular system. By utilizing a targeting antibody conjugated to an oligonucleotide payload, the therapy seeks to overcome the delivery challenges typically associated with systemic administration of genetic medicines. As of early 2024, the program is in the discovery stage, and specific molecular targets or clinical indications have not been disclosed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Muscle Targeted AOC.